Last update June 30, 2022
Very Low Risk
A central nervous system stimulant and indirect sympathomimetic with actions and indications similar to dexamfetamine. Indicated in attention-deficit hyperactivity disorder (ADHD) and in narcolepsy. Oral administration 1 to 3 times a day.
It is excreted in breastmilk in clinically insignificant amounts or not at all (Collin 2018, Bolea 2014, Spigset 2007, Hackett 2006) and no short or long term problems have been observed in infants whose mothers were taking it. (Collin 2018, Rowe 2013, Bolea 2014, Spigset 2007, Hackett 2006)
The plasma levels of these infants were undetectable or very low. (Bolea 2014, Hackett 2006)
Several medical associations and experts consider the use of this medication to be safe during breastfeeding. (Calvo 2018, Collin 2018, Ornoy 2018, Marchese 2015, Rowe 2013)
Some authors suggest clinically monitoring weight gain and possible irritability in the infant. (Marchese 2015, Rowe 2013)
Methylphenidate does not influence prolactin levels on a regular basis (Janowsky 1978), but increased milk production (Bello 2022) and galactorrhoea (Ekinci 2017) have been described.
We do not have alternatives for Methylphenidate since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM